FindTrial
Sign In

Diagnosis of pubertal disorders

To study the utility of basal and FSH stimulated Inhibin B in pubertal disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/10/021570
Enrollment
96
Registered
2019-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E309- Disorder of puberty, unspecified

Interventions

Intervention1: Inj FSH: Girls- INJ FSH 150 IU im for 3 days,sample to be taken on D1 and D4
Boys: Inj FSH 300 IU im at D1,D3 and D5 ,sample to be taken on D1 and D6 ( sample to be taken for LH,FSH,Estrogen,Testosterone,Inhibin B and AMH) Control Intervention1: Inj Triptorelin: Inj Triptoreli
Blood sample to be taken at baseline (LH,FSH,Estrogen,Testosterone), 4 hour (LH and FSH) and 24 hour ( Estrogen,Testosterone and Inhibin B ) after injection

Sponsors

Dr Rama Walia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Precocious Puberty,premature adrenarche,premature thelarche,anterior pituitary hormone deficiency,Delayed puberty,Children with normal puberty(controls)

Exclusion criteria

Exclusion criteria: Hypogonadotropic Hypogonadism on treatment with hCG and HMG. Hypergonadotrpic Hypogonadism

Design outcomes

Primary

MeasureTime frame
FSH stimulated Inhibin B as marker of onset of puberty. Timepoint: 12 months—

Secondary

MeasureTime frame
Basal Inhibin B, AMH and Inhibin B/AMH ratio as a marker of entry into puberty.Timepoint: 12 months;Effect of GnRH analogue stimulation on Inhibin B.Timepoint: 12 months—

Countries

India

Contacts

Public ContactDr Shakun Chaudhary

PGIMER,Chandigarh

shakunchaudhary@yahoo.co.in9418233513

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 14, 2026